Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mannkind Corp (MNKD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 215,950
  • Shares Outstanding, K 187,783
  • Annual Sales, $ 27,860 K
  • Annual Income, $ -86,980 K
  • 60-Month Beta 2.53
  • Price/Sales 7.89
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.10
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.11 +9.01%
on 05/28/19
1.35 -10.04%
on 05/20/19
-0.06 (-4.72%)
since 05/17/19
3-Month
1.11 +9.01%
on 05/28/19
2.34 -48.29%
on 03/20/19
-0.99 (-45.00%)
since 03/15/19
52-Week
0.94 +28.72%
on 12/27/18
3.04 -60.20%
on 09/05/18
-0.69 (-36.32%)
since 06/15/18

Most Recent Stories

More News
MannKind to Present at the JMP Securities Life Sciences Conference

MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension,...

MNKD : 1.22 (+6.09%)
MannKind Presents Positive Afrezza(R) Clinical Data from Three Studies at ADA 79th Scientific Sessions

MannKind Corporation (Nasdaq: MNKD) announced that new data from three different studies of Afrezza(R) (insulin human) Inhalation Powder were released at the American Diabetes Association's 79th Scientific...

MNKD : 1.22 (+6.09%)
MannKind Announces Afrezza(R) Distribution Agreement in Australia

MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd....

MNKD : 1.22 (+6.09%)
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.

LLY : 112.98 (+1.11%)
ARNA : 57.07 (+3.16%)
MNKD : 1.22 (+6.09%)
UTHR : 79.15 (+1.18%)
MannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019

MannKind Corporation (Nasdaq:MNKD) will release its 2019 first quarter financial results on Tuesday, May 7, 2019 and its management will host a conference call to discuss the financial results and other...

MNKD : 1.22 (+6.09%)
MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019)

MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be presented in an e-poster presentation on Thursday, April 25, 2019 at the 28...

MNKD : 1.22 (+6.09%)
Detailed Research: Economic Perspectives on MannKind, Sonic Automotive, Five Prime Therapeutics, CONMED, Cohu, and FTI Consulting -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MannKind Corporation (NASDAQ:MNKD),...

FCN : 84.29 (+0.62%)
FPRX : 6.34 (+7.46%)
COHU : 15.93 (+1.53%)
SAH : 23.31 (-0.60%)
CNMD : 83.42 (+1.21%)
MNKD : 1.22 (+6.09%)
MannKind to Present at the H.C. Wainwright Global Life Sciences Conference

MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension,...

MNKD : 1.22 (+6.09%)
MannKind Receives $12.5 Million Milestone Payment from United Therapeutics

MannKind Corporation (NASDAQ: MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the...

UTHR : 79.15 (+1.18%)
MNKD : 1.22 (+6.09%)
Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance

Veeva Systems (NYSE:VEEV) today announced that life sciences companies are adopting Veeva Nitro to accelerate their data warehouse projects and deliver faster insights to the...

VEEV : 166.54 (+1.16%)
KPTI : 6.01 (+5.25%)
MNKD : 1.22 (+6.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade MNKD with:

Business Summary

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder...

See More

Key Turning Points

2nd Resistance Point 1.20
1st Resistance Point 1.17
Last Price 1.22
1st Support Level 1.13
2nd Support Level 1.12

See More

52-Week High 3.04
Fibonacci 61.8% 2.24
Fibonacci 50% 1.99
Fibonacci 38.2% 1.74
Last Price 1.22
52-Week Low 0.94

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar